TargetBeta
MYH6
myosin heavy chain 6 · Myosin heavy chains, class II
3 programs in company-led studies act on MYH6, from 2 companies: 2 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| mavacamtenrule | Bristol-Myers Squibb | inhibitor | phase 4 | 214 running | MYH7, MYH7B, MYL2, MYL3, MYL4, MYL7 | ChEMBL |
| danicamtivrule | Bristol-Myers Squibb | agonist | phase 3 | 72 running | MYH7, MYH7B, MYL2, MYL3, MYL4, MYL7 | ChEMBL |
| omecamtiv mecarbilrule | Cytokinetics | agonist | phase 3 | 161 running | MYH7, MYH7B, MYL2, MYL3, MYL4, MYL7 | ChEMBL |
Conditions their studies are in
- Heart Failure, 2 programs
- Anthrax, 1 program
- Cardiomyopathy, Dilated, 1 program
- Cardiomyopathy, Hypertrophic, 1 program
- Ventricular Dysfunction, Left, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Sep 2027danicamtiv · Bristol-Myers Squibb · phase 3 · NCT07210723
- Sep 2027omecamtiv mecarbil · Cytokinetics · phase 3 · NCT06736574
- Dec 13, 2027mavacamten · Bristol-Myers Squibb · phase 4 · NCT07004972
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.